Synlogic (NASDAQ:SYBX) Share Price Crosses Below Fifty Day Moving Average of $2.11

Synlogic Inc (NASDAQ:SYBX) shares passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $2.11 and traded as low as $2.01. Synlogic shares last traded at $2.01, with a volume of 48,967 shares traded.

A number of equities research analysts recently weighed in on the company. Chardan Capital restated a “buy” rating and issued a $5.00 price target on shares of Synlogic in a report on Friday, September 18th. HC Wainwright restated a “buy” rating on shares of Synlogic in a report on Monday, August 10th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $6.94.

The firm has a market cap of $68.67 million, a price-to-earnings ratio of -1.21 and a beta of 2.15. The company has a debt-to-equity ratio of 0.16, a quick ratio of 20.18 and a current ratio of 20.18. The business has a fifty day moving average of $2.11 and a two-hundred day moving average of $2.14.

Synlogic (NASDAQ:SYBX) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.02. The firm had revenue of $0.45 million for the quarter, compared to analysts’ expectations of $0.35 million. Synlogic had a negative return on equity of 38.34% and a negative net margin of 2,761.83%. On average, equities research analysts forecast that Synlogic Inc will post -1.84 earnings per share for the current year.

A number of large investors have recently made changes to their positions in the business. Nuveen Asset Management LLC grew its holdings in Synlogic by 12.1% during the 1st quarter. Nuveen Asset Management LLC now owns 56,597 shares of the biotechnology company’s stock valued at $97,000 after buying an additional 6,113 shares during the last quarter. State Street Corp grew its holdings in Synlogic by 2.4% during the 1st quarter. State Street Corp now owns 302,915 shares of the biotechnology company’s stock valued at $521,000 after buying an additional 7,162 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Synlogic by 4.7% during the 1st quarter. JPMorgan Chase & Co. now owns 370,699 shares of the biotechnology company’s stock valued at $638,000 after buying an additional 16,582 shares during the last quarter. Wells Fargo & Company MN grew its holdings in Synlogic by 288.3% during the 1st quarter. Wells Fargo & Company MN now owns 26,945 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 20,005 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Synlogic by 12.3% during the 1st quarter. Geode Capital Management LLC now owns 281,429 shares of the biotechnology company’s stock valued at $484,000 after buying an additional 30,872 shares during the last quarter. Hedge funds and other institutional investors own 44.18% of the company’s stock.

Synlogic Company Profile (NASDAQ:SYBX)

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

See Also: What Is Dividend Yield and How Do You Calculate It?

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.